Residual Inflammatory Risk-Guided colcHicine in Elderly Trial

Summary

The goal of this clinical trial is to compare low-dose colchicine (0.5 mg Once Daily) with no specific intervention in selected elderly patients (60-80 years old) with residual inflammatory risk (hs-CRP≥ 2mg/L) and multivessel coronary artery disease. The main questions it aims to answer are: * Whether the intervention is effective in reducing ischemic events * Whether the intervention is effective in reducing inflammatory biomarkers' level * Whether the intervention is safe for elderly patients Participants will be randomized to receive low-dose colchicine (0.5 mg Once Daily) or no specific intervention for one year. Patients enrolled should complete one-year follow-up in the form of clinic visit or telephone call.

Timeline

Start

2023-09

Primary completion

2025-09

Completion

2025-10

Drugs

Indications